News Releases

News Releases

Date Title
Dec 11, 2018 Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Dec 10, 2018 Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Dec 10, 2018 Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
Dec 06, 2018 Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
Nov 15, 2018 Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
Nov 07, 2018 Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Nov 06, 2018 Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Sep 26, 2018 Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
Sep 25, 2018 Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Sep 25, 2018 Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
Sep 05, 2018 Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Aug 08, 2018 Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
Jun 15, 2018 Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association
Jun 05, 2018 Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology
May 31, 2018 Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 17, 2018 Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association
May 09, 2018 Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 01, 2018 Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Apr 25, 2018 Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting
Apr 18, 2018 Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer
Mar 14, 2018 Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Mar 07, 2018 Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
Mar 01, 2018 Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting
Feb 28, 2018 Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Feb 15, 2018 Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Feb 14, 2018 Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Feb 13, 2018 Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Feb 12, 2018 Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
Jan 08, 2018 Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment